PT  - JOURNAL ARTICLE
AU  - Lefèvre, Benjamin
AU  - Tondeur, Laura
AU  - Madec, Yoann
AU  - Grant, Rebecca
AU  - Lina, Bruno
AU  - van der Werf, Sylvie
AU  - Rabaud, Christian
AU  - Fontanet, Arnaud
AU  - Legoff, Antoine
TI  - Impact of B.1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort study
AID  - 10.1101/2021.07.28.21261285
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.28.21261285
4099  - http://medrxiv.org/content/early/2021/07/31/2021.07.28.21261285.short
4100  - http://medrxiv.org/content/early/2021/07/31/2021.07.28.21261285.full
AB  - Background We aimed to assess the effectiveness of the BNT162b2 mRNA vaccine against B.1.351 (beta) variant among residents of long-term care facilities (LCTFs) in eastern France.Methods We used routinely collected surveillance and COVID-19 vaccination data to conduct a retrospective cohort study of SARS-CoV-2 B.1.351 infection incidence and vaccine effectiveness among LCTFs residents in eastern France between 15 January and 19 May 2021. Data from secondary RT-PCR screening were used to identify B.1.351 variants.Findings Included in our analysis were 378 residents from five LCTFs: 287 (76%) females, with median (IQR) age of 89 (83-92) years. Two B.1.351 outbreaks took place in LTCFs in which more than 70% of residents had received two doses of BNT162b2 mRNA vaccine, which included 11 cases of severe disease and six deaths among those who had received two doses. Vaccine effectiveness (95% CI) seven days after the second dose of vaccine was 49% (14-69) against any infection with B.1.351 and 86% (67-94) against severe forms of COVID-19. In multivariable analysis, females were less likely to develop severe forms of disease (IRR = 0.35, 95% CI = 0.20-0.63).Interpretation We observed reduced vaccine effectiveness associated with B.1.351, as well as B.1.351 outbreaks in two LTCFs among individuals who had received two doses of vaccine. Our findings highlight the need to maintain SARS-CoV-2 surveillance in these high-risk settings beyond the current COVID-19 mass vaccination campaign, and advocate for a booster vaccine dose prior to the next winter season.Competing Interest StatementBenjamin Lefevre reports travel funding from ViiV (2019) and Gilead (2020), outside the submitted work. All other authors have no competing interests. Funding StatementThis study has benefited from financial support from the French Ministry of Health and Solidarity.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In France, surveillance of COVID-19 testing and COVID-19 vaccination data in LTCFs is considered as public health surveillance which does not require formal ethical review. The pseudonymized data collection by medical personnel at the LTCFs and analysis by the authors have been performed under the legal responsibility of the Societe de Pathologie Infectieuse de Langue Francaise, which ensured compliance with data protection regulations in France.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the Societe de Pathologie Infectieuse de Langue Francaise. Restrictions apply to the availability of these data, which were used under authorized agreement for this study by the Societe de Pathologie Infectieuse de Langue Francaise, which ensures compliance with data protection regulations in France. Access to these data would therefore require prior authorization by the Societe de Pathologie Infectieuse de Langue Francaise.